Erratum: The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI (Journal of Cerebral Blood Flow and Metabolism (2014) 34 (1328-39) DOI: 10.1038/jcbfm.2014.87);The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 8, 2014, Pages 1328-1339

  Wagner, Amy K ^a   Scanlon, Joelle M ^a   Becker, Carl R ^c   Ritter, Anne C ^a   Niyonkuru, Christian ^a   Dixon, Clifton E ^a,b   Conley, Yvette P ^b,d   Price, Julie C ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

CFT; dopamine; genetic variation; PET imaging; raclopride; traumatic brain injury;

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BETA CFT C 11; CLONAZEPAM; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE TRANSPORTER; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; ALLELE; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; GENETIC VARIABILITY; GENOTYPE; GLASGOW COMA SCALE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; MALE; MOLECULAR PHYLOGENY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN INTERACTION; PUTAMEN; RECEPTOR BINDING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SLEEP; TRAUMATIC BRAIN INJURY; VARIABLE NUMBER OF TANDEM REPEAT;

AGE FACTORS; BRAIN INJURIES; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLASGOW COMA SCALE; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIVARIATE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PUTAMEN; RECEPTORS, DOPAMINE D2; TANDEM REPEAT SEQUENCES;

EID: 84905436221     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.176     Document Type: Erratum

References (45)

1. Crosson B, Halland K. Subcortical functions in cognition: toward a consensus. J Int Neuropsychol Soc 2003; 9: 1027-1030.
2. Bales J, Wagner AK, Kline AE, Dixon CE. Persistent cognitive dysfunction during rehabilitation of traumatic brain injury: towards a dopamine hypothesis. Neurosci Biobehav Rev 2009; 33: 981-1003.
3. Wagner AK, Ren D, Conley Y, Ma X, Kerr ME, Zafonte RD et al. Gender and genetic associations with CSF dopamine and metabolite production after severe TBI. J Neurosurg 2007; 106: 537-547.
4. Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G et al. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med 2000; 27: 1410-1414.
5. Wagner AK, Sokoloski JE, Ren D, Chen X, Khan AS, Zafonte RD et al. Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J Neurochem 2005; 95: 457-465.
6. Wagner AK, Drewencki L, Chen X, Santos FR, Khan AS, Harun R et al. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury. J Neurochem 2009; 108: 986-997.
7. Warden DL, Gordon B, McAllister TW, Silver JM, Barth JT, Bruns J et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006; 23: 1468-1501.
8. Gu Z, Feng X, Dong X, Chan P. Smoking, genes encoding dopamine pathway and risk for Parkinson's disease. Neurosci Lett 2010; 482: 31-34.
9. Xu X, Mill J, Sun B, Chen CK, Huang YS, Wu YY et al. Association study of promoter polymorphisms at the dopamine transporter gene in attention deficit hyperactivity disorder. BMC Psychiatry 2009; 9: 3.
10. Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. J Am Med Assoc 1991; 266: 1793-1800.
11. Genro JP, Polanczyk GV, Zeni C, Oliveira AS, Roman T, Rohde LA et al. A common haplotype at the dopamine transporter gene 5' region is associated with attention- deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1568-1575.
12. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA et al. Amphetamine- induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96.
13. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 2002; 27: 87-299.
14. Forsback S, Marjamaki P, Eskola O, Bergman J, Rokka J, Gronroos T et al. [18F]CFT synthesis and binding to monoamine transporters in rats. EJNMMI Res 2012; 2: 3.
15. Zhen J, Ali S, Dutta AK, Reith ME. Characterization of [3H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive. J Neurosci Methods 2012; 203: 19-27.
16. Hoffman AF, Lupica CR, Gerhardt GA. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J Phramacol Exp Ther 1998; 287: 487-496.
17. Gurevich EV, Joyce JN. Distributuion of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999; 20: 60-80.
18. Seeman P, Wilson A, Gmeiner P, Kapur S. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 2006; 60: 205-211.
19. Nagren K, Muller L, Halldin C, Swahn CG, Lehikoinen P. Improved synthesis of some commonly used PET radioligands by the use of [11C]methyl triflate. Nucl Med Biol 1995; 22: 235-239.
20. Halldin C, Farde L, Hogberg T, Hall H, Strom P, Ohlberger A et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int J Rad Appl Instrum B 1991; 18: 871-881.
21. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse 1993; 15: 130-142.
22. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999; 40: 2053-2065.
23. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol 2003; 30: 833-844.
24. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 2002; 12: 1440-1452.
25. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gunn RN, Holden J et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
26. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-287.
27. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155: 344-349.
28. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133-139.
29. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005; 46: 745-751.
30. Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early parkinson's disease: compartment analysis for b-CFT binding with positron emission tomography. Ann Neurol 1999; 45: 601-610.
31. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57: 470-475.
32. Lin Z, Canales JJ, Björgvinsson T, Thomsen M, Qu H, Liu QR et al. Monoamine transporters: vulnerable and vital doorkeepers. Prog Mol Biol Transl Sci 2011; 98: 1-46.
33. McDougall SA, Der-Ghazarian T, Britt CE, Varela FA, Crawford CA. Postnatal manganese exposure alters the expression of D2L and D2S receptor isoforms: relationship to PKA activity and Akt levels. Synapse 2011; 65: 583-591.
34. Rumpel R, Alam M, Klein A, Ozer M, Wesemann M, Jin X et al. Neuronal firing activity and gene expression changes in the subthalamic nucleus after transplantation of dopamine neurons in hemiparkinsonian rats. Neurobiol Dis 2013; 59: 230-243.
35. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14: 169-177.
36. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28: 73-82.
37. Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet 1997; 74: 162-166.
38. Frank MJ, Hutchison K. Genetic contributions to avoidance-based decisions: striatal D2 receptor polymorphisms. Neuroscience 2009; 164: 131-140.
39. Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, Romano R et al. Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One 2010; 5: e9348.
40. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12: 205-216.
41. Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 2010; 64: 146-151.
42. Bruck A, Portin R, Lindell A, Laihinen A, Bergman J, Haaparanta M et al. Positron emission tomography shows that impaired frontal lobe functioning in parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001; 311: 81-84.
43. Rohde LA, Roman T, Szobot C, Cunha RD, Hutz MH, Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse 2003; 48: 87-89.
44. Zhang ZY, Zhang Z, Fauser U, Schluesener HJ. Global hypomethylation defines a sub-population of reactive microglia/macrophages in experimental traumatic brain injury. Neurosci Lett 2007; 429: 1-6.
45. Abdolmaleky HM, Smith CL, Zhou JR, Thiagalingam S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol 2008; 448: 187-212.